SF3B1 and BAP1 mutations in blue nevus-like melanoma
Klaus Griewank(Düsseldorf University Hospital), Dirk Schadendorf(National Center for Tumor Diseases)
Cited by 101
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Mutations in <i>GNA11</i> in Uveal Melanoma
|New England Journal of Medicine|2010|1.5k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k